research Characterization of Novel TMEM173 Mutation with Additive IFIH1 Risk Allele
A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.
Search
forLearn
0 / 0 results — no results
Research
5 / 352 results 
research Minoxidil Activates β-Catenin Pathway in Human Dermal Papilla Cells: A Possible Explanation for Its Anagen Prolongation Effect
Minoxidil helps hair growth by activating the β-catenin pathway.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Downstream Molecular Responses to Volatile Signaling in Roots
Plant roots respond to fungus smells by possibly using certain proteins and a plant hormone to change root growth, but more research is needed.
research The Chemokine SDF-1/CXCL12 Regulates the Migration of Melanocyte Progenitors in Mouse Hair Follicles
SDF-1/CXCL12 and its receptor CXCR4 are crucial for melanocyte movement in mouse hair follicles.
Community Join
5 / 54 resultscommunity Amplifica AMP-303 study results are expected late this summer
by
hzah1
in Research/Science
16 upvotes
6 months ago Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
by hzah1
in Research/Science
35 upvotes
9 months ago Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
by hzah1
in Treatment
39 upvotes
4 months ago AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community Amplifica and AMP-303 clinical phase 1
by
Additional-Bed2165
in Research/Science
8 upvotes
1 year ago Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Expectations control for SCUBE3
by
ralfp
in Research/Science
20 upvotes
10 months ago SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.